{
    "id": 26032,
    "fullName": "ALK E1303K",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "ALK E1303K lies within the protein kinase domain of the Alk protein (UniProt.org). E1303K has been identified in the scientific literature (PMID: 29978950), but has not been biochemically characterized and therefore, its effect on Alk protein function is unknown (PubMed, Sep 2019).",
            "references": [
                {
                    "id": 12134,
                    "pubMedId": 29978950,
                    "title": "Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29978950"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 238,
        "geneSymbol": "ALK",
        "terms": [
            "ALK",
            "CD246",
            "NBLST3"
        ]
    },
    "variant": "E1303K",
    "createDate": "02/09/2017",
    "updateDate": "09/30/2019",
    "referenceTranscriptCoordinates": {
        "id": 102015,
        "transcript": "NM_004304",
        "gDna": "chr2:g.29207202C>T",
        "cDna": "c.3907G>A",
        "protein": "p.E1303K",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 18603,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a patient with non-small cell lung cancer harboring EML4-ALK and ALK E1303K developed progressive disease 7 days after Xalkori (crizotinib) treatment (PMID: 29978950).",
            "molecularProfile": {
                "id": 33476,
                "profileName": "EML4 - ALK ALK E1303K"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 12134,
                    "pubMedId": 29978950,
                    "title": "Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29978950"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 27174,
            "profileName": "ALK E1303K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33476,
            "profileName": "EML4 - ALK ALK E1303K",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 102015,
            "transcript": "NM_004304",
            "gDna": "chr2:g.29207202C>T",
            "cDna": "c.3907G>A",
            "protein": "p.E1303K",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}